AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01033825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA Nasal Aerosol 320 mcg
Description: Ciclesonide HFA Nasal Aerosol 320 μg once daily
Study NCT01033825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA Nasal Aerosol 160 mcg
Description: Ciclesonide HFA Nasal Aerosol 160 μg once daily
Study NCT01033825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HFA Nasal Aerosol placebo
Description: HFA Nasal Aerosol placebo once daily
Study NCT01033825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide Aqueous Nasal Spray 200 mcg
Description: Ciclesonide Aqueous Nasal Spray 200 mcg once daily
Study NCT01033825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AQ Nasal Spray Placebo
Description: AQ Nasal Spray Placebo once daily
Study NCT01033825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Dexamethasone HFA
Description: Dexamethasone capsules 6 mg once daily
Study NCT01033825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo AQ plus Dexamethasone 6 mg
Description: Placebo AQ plus Dexamethasone 6 mcg capsules once daily
Study NCT02913690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 150mg capsules daily
Study NCT02913690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRF
Description: 2 x 150mg capsules daily
Study NCT00755274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine No Preservative: Pediatric Dose
Description: 0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
Study NCT01868880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine plus beta-blocker (bisoprolol)
Description: Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
Study NCT01868880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betablocker titration
Description: Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
Study NCT03757286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FSF with CAD\CAM customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction.
Study NCT03757286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FSF without customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed.
Study NCT02904915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
Study NCT02904915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No analgesia
Description: IUD placement without analgesia.
Study NCT02904915 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine device (IUD)
Description: IUD placement with or without paracervical block with 1% lidocaine.
Study NCT03019042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi
Description: Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
Study NCT03019042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
Study NCT01422122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000 mg per day, one tablespoon syrup per day
Study NCT01422122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one table spoon Syrup per day
Study NCT00550680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
Study NCT04020601 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic injection
Study NCT04020601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic injection
Study NCT04020601 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dextrose
Description: Sham injection
Study NCT04020601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: Sham injection
Study NCT03693625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
Study NCT03693625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GDC-0853
Description: Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
Study NCT02731261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor memory consolidation
Description: Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
Study NCT04754880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of oxidative and antioxidative markers between groups
Description: Oxidant and anti-oxidant markers
Study NCT03912675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integra® dermal substitute and RigeneraTM protocol
Description: Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol
Study NCT02725983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPT consultation
Study NCT02725983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPT consultation
Study NCT02725983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOPROCARE®
Study NCT02997904 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Apply Liquid Then Comb Out
Description: Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
Study NCT02997904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apply Liquid Then Comb Out
Description: Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
Study NCT01246570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The patients will meet for organized exercise training once monthly and also exercise testing every third month.
Study NCT01246570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients will receive the usual care provided by the hospitals and the community health services
Study NCT01986413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilation BIPAP ST
Description: spontaneous timed pressure controled bilevel ventilation
Study NCT01986413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: volume assured pressure support IVAPS
Description: intelligent volume assured Pressure Support
Study NCT01986413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
Study NCT01986413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
Study NCT00411359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Phase III cardiac rehabilitation programme
Study NCT02874456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virus detection
Description: Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
Study NCT02043548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
Study NCT02043548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
Study NCT01483781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
Study NCT01483781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
Study NCT02994433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
Study NCT02994433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gas
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Study NCT02994433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
Study NCT02994433 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
Study NCT04519411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure measurements
Description: Transpulmonary pressure measurements
Study NCT03209206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
Study NCT03209206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Normal saline
Description: Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
Study NCT02947152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT288
Description: Cadherin-6-targeting antibody-drug conjugate for intravenous administration
Study NCT02346032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: refametinib
Description: Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
Study NCT01223170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored content
Description: Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
Study NCT01223170 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic Internet-based information
Description: Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
Study NCT01223170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic Internet-based information
Description: Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
Study NCT01223170 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Discussion forum
Description: Access to a discussion forum for Cardiovascular Disease Rehabilitation.
Study NCT01223170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion forum
Description: Access to a discussion forum for Cardiovascular Disease Rehabilitation.
Study NCT01223170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral monitoring
Description: Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
Study NCT00254748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: flexible doses from 200 mg to 600 mg
Study NCT00254748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02716051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Whole body MRI with cardiac and pulmonary synchronization
Study NCT02716051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET
Study NCT02993874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
Study NCT02993874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
Study NCT02100436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Description: A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
Study NCT00150826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinapril
Description: Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
Study NCT00150826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in a capsule form once daily for 16 weeks.
Study NCT01392677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
Study NCT01392677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
Study NCT03402984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acotiamide
Description: Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
Study NCT03402984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
Study NCT02781909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
Study NCT02781909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care TB treatment
Description: Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
Study NCT02781909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care TB treatment
Description: Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
Study NCT04232228 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention was used in this study.
Study NCT04127253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sooma transcranial direct current stimulation device plus Brain training tools
Description: This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
Study NCT04127253 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools
Description: This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
Study NCT04127253 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Brain training tools in isolation
Description: This group will act as a control, they will only carry out the training of action observation and motor imagery.
Study NCT02404623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
Study NCT02404623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
Study NCT02858908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: Tideglusib for oral suspension,
Study NCT04563494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Prevention of post op nausea and vomiting
Study NCT03853239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: face mask ventilation crossover nasal ventilation
Description: Group A was first ventilated through the face mask, and the tidal volume was measured under pressure-controlled mode (10, 15, 20 cm H2O) ;Switched to volume-controlled (6,8,10ml/kg predicted body weight)mode, the actual tidal volume was recorded, and the air leakage was calculated. Then, put a nasal RAE tube in one side of the nostril, inflate the cuff, make the catheter in a natural position after inflation, clip the other side of the nostril, close the lip with tape, connect the breathing circuit, record the actual tidal volume; measure the expired tidal volume during pressure-controlled ventilation (10, 15, 20 cm H2O).Subject will start with one technique and then cross over to the other technique.